Moderna, Inc. DEF 14A Filing

Ticker: MRNA · Form: DEF 14A · Filed: Mar 21, 2024 · CIK: 1682852

Moderna, Inc. DEF 14A Filing Summary
FieldDetail
CompanyModerna, Inc. (MRNA)
Form TypeDEF 14A
Filed DateMar 21, 2024
Risk Level
Pages15
Reading Time18 min
Key Dollar Amounts$6.7 billion, $13.3 billion
Sentimentneutral

Sentiment: neutral

Topics: Moderna, MRNA, DEF 14A, SEC Filing, Executive Compensation

TL;DR

<b>Moderna, Inc. filed its DEF 14A with the SEC on March 21, 2024, detailing executive compensation and corporate information.</b>

AI Summary

Moderna, Inc. (MRNA) filed a Proxy Statement (DEF 14A) with the SEC on March 21, 2024. Moderna, Inc. filed a DEF 14A with the SEC on March 21, 2024. The filing covers the period ending May 6, 2024. The company's principal executive offices are located at 200 Technology Square, Cambridge, MA. Moderna was formerly known as Moderna Therapeutics, Inc., with a name change on August 22, 2016. The filing includes detailed executive compensation data for PEO and Non-PEO members for fiscal years 2020-2023.

Why It Matters

For investors and stakeholders tracking Moderna, Inc., this filing contains several important signals. This filing provides crucial information about executive compensation packages, which can influence investor perception and executive retention. The DEF 14A filing is a key document for shareholders to understand the company's governance and how executive pay is structured.

Risk Assessment

Risk Level: — Moderna, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, providing standard corporate disclosures without immediate financial or operational red flags.

Analyst Insight

Review the executive compensation details to understand pay structures and potential impacts on shareholder value.

Key Numbers

  • 2024-03-21 — Filing Date (DEF 14A filing date)
  • 2024-05-06 — Period of Report (Conformed period of report)
  • 2016-08-22 — Name Change Date (Date of former company name change)

Key Players & Entities

  • Moderna, Inc. (company) — Filer
  • Moderna Therapeutics, Inc. (company) — Former company name
  • 200 Technology Square, Cambridge, MA (company) — Business address

FAQ

When did Moderna, Inc. file this DEF 14A?

Moderna, Inc. filed this Proxy Statement (DEF 14A) with the SEC on March 21, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Moderna, Inc. (MRNA).

Where can I read the original DEF 14A filing from Moderna, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Moderna, Inc..

What are the key takeaways from Moderna, Inc.'s DEF 14A?

Moderna, Inc. filed this DEF 14A on March 21, 2024. Key takeaways: Moderna, Inc. filed a DEF 14A with the SEC on March 21, 2024.. The filing covers the period ending May 6, 2024.. The company's principal executive offices are located at 200 Technology Square, Cambridge, MA..

Is Moderna, Inc. a risky investment based on this filing?

Based on this DEF 14A, Moderna, Inc. presents a moderate-risk profile. The filing is a routine DEF 14A, providing standard corporate disclosures without immediate financial or operational red flags.

What should investors do after reading Moderna, Inc.'s DEF 14A?

Review the executive compensation details to understand pay structures and potential impacts on shareholder value. The overall sentiment from this filing is neutral.

How does Moderna, Inc. compare to its industry peers?

Moderna operates in the biotechnology sector, focusing on mRNA therapeutics and vaccines.

Are there regulatory concerns for Moderna, Inc.?

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information to shareholders.

Industry Context

Moderna operates in the biotechnology sector, focusing on mRNA therapeutics and vaccines.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information to shareholders.

What Investors Should Do

  1. Analyze the executive compensation table for key executives.
  2. Note any changes in corporate governance disclosures.
  3. Verify the period of report and filing date for accuracy.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a proxy statement typically filed annually to provide information to shareholders for voting purposes. Specific comparative data from a previous filing is not directly available in this snippet.

Filing Stats: 4,487 words · 18 min read · ~15 pages · Grade level 12.9 · Accepted 2024-03-21 08:46:38

Key Financial Figures

  • $6.7 billion — ugh mRNA medicines. 2023 Performance $6.7 billion 48% U.S. market share 9 late-stag
  • $13.3 billion — d late-stage programs for PA and MMA. $13.3 billion 45 programs 19 markets in cash, c

Filing Documents

Executive Compensation

Executive Compensation 73 Compensation and Talent Committee Report 74

Security Ownership of Certain

Security Ownership of Certain Beneficial Owners and Management 76 Proposal No. 3: Ratification of Appointment of Independent Registered Public Accounting Firm 78 Audit Committee Report 79 Proposal No. 4: Amend Our Certificate of Incorporation to Provide Shareholders the Right to Call a Special Meeting 81 Proposal No. 5: Amend Our Certificate of Incorporation to Reflect New Delaware Law Provisions Allowing for Officer Exculpation 83 Information about the 2024 Annual Meeting of Shareholders 88 Appendix A 89 Appendix B Back to Contents Notice of Annual Meeting of Shareholders MONDAY, MAY 6, 2024 8:00 a.m., Eastern Time www.virtualshareholdermeeting.com/MRNA2024 HOW TO VOTE Review your proxy statement and vote in one of three ways: Internet www.proxyvote.com Telephone 1-800-690-6903 Mail Complete, sign, date, and return your proxy card or voting instruction form YOUR VOTE IS IMPORTANT . Even if you plan to participate in the Annual Meeting, we urge you to submit your proxy in advance to ensure your shares are represented. This will not affect your right to participate in the meeting and to vote your shares at that time. For additional information on voting and participating in the meeting, please see "Information About the 2024 Annual Meeting of Shareholders" beginning on page 83. To the Shareholders of Moderna, Inc.: You are cordially invited to the Annual Meeting of Shareholders of Moderna, Inc., which will be held on Monday, May 6, 2024, beginning at 8:00 a.m., Eastern Time (the Annual Meeting), for the following purposes: 1. To elect three Class III directors, each to serve for a three-year term expiring at the 2027 annual meeting of shareholders; 2. To approve, on a non-binding, advisory basis, the compensation of our named executive officers; 3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024; 4. To appr

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.